Severe Acute Respiratory Syndrome (SARS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 70 pages | ID: SD0B0A15E345EN
VPAResearch

Abstracts

Severe Acute Respiratory Syndrome (SARS) Drug pipeline report- 2020 is an annual R&D review of Severe Acute Respiratory Syndrome (SARS) pipeline candidates. The report presents the current status of all major Severe Acute Respiratory Syndrome (SARS) therapeutic compounds. Detailed insights into Severe Acute Respiratory Syndrome (SARS) pipeline development, current status, companies, drug profiles and Severe Acute Respiratory Syndrome (SARS) preclinical and clinical trials are included.

2020 Severe Acute Respiratory Syndrome (SARS) Pipeline Market Insights
Severe Acute Respiratory Syndrome (SARS) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Severe Acute Respiratory Syndrome (SARS) therapies, pipeline by phase and others are included.

Severe Acute Respiratory Syndrome (SARS) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Severe Acute Respiratory Syndrome (SARS) Therapeutic Drug candidates
Both active and inactive Severe Acute Respiratory Syndrome (SARS) pipeline drug candidates are included in the report

Severe Acute Respiratory Syndrome (SARS) Clinical Trials and preclinical Studies
Severe Acute Respiratory Syndrome (SARS) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Severe Acute Respiratory Syndrome (SARS) pipeline market developments
Severe Acute Respiratory Syndrome (SARS) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Severe Acute Respiratory Syndrome (SARS) pipeline companies in active development
The report analyzes Severe Acute Respiratory Syndrome (SARS) pipeline of the below companies-

Atriva Therapeutics GmbH, Autoimmune Technologies LLC, Biotron Ltd , CEL-SCI Corp, Fab’entech SA, GeneCure LLC, Gilead Sciences Inc, Global BioLife Inc Ltd, MassBiologics, Novavax Inc, Oncovir Inc, Phelix Therapeutics LLC, Sagimet Biosciences

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
13 Companies investing in Severe Acute Respiratory Syndrome (SARS) pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Severe Acute Respiratory Syndrome (SARS) pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE MARKET INSIGHTS, 2020

1.1 Severe Acute Respiratory Syndrome (SARS) Disease Overview
1.2 Severe Acute Respiratory Syndrome (SARS) Drug Pipeline Snapshot, 2020
  1.2.1 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Phase
  1.2.2 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Company
  1.2.3 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Mechanism of Action
  1.2.4 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Route of Administration

2. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) COMPANY WISE PIPELINE DETAILS

Atriva Therapeutics GmbH Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Autoimmune Technologies LLC Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Biotron Ltd Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
CEL-SCI Corp Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Fab’entech SA Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Gilead Sciences Inc Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Global BioLife Inc Ltd Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
MassBiologics Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Novavax Inc Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Oncovir Inc Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Phelix Therapeutics LLC Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sagimet Biosciences Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts